PRP for pattern hair loss

What is the proposed target?

PRP is a platelet-enriched portion of your blood proposed to influence follicular activity; it does not create an unlimited new supply of follicles or transplant hair. Preparations differ in composition and processing. “More concentrated” or “more growth factors” does not by itself establish greater effectiveness. Hair density and shaft diameter should be assessed separately from a subjective impression of fullness.

Section sources: Health Canada · Position on PRP and PRF treatments (2019 notice) · Meta-analysis · PRP for androgenetic alopecia (2024)

When diagnosis takes priority

Rapid or patchy loss, pain or burning, scale or pus, or smooth shiny areas lacking follicular openings require assessment. Scarring inflammation can permanently destroy follicles, making delay important. Deficiencies, illness-related shedding, postpartum loss and hereditary thinning may coexist. Blood tests or biopsy should be selected from the clinical findings rather than purchased as a universal panel.

Section sources: AAD · Hair loss diagnosis and treatment · AAD · Hair loss signs requiring diagnosis · AAD · Causes of hair loss including scarring alopecia

Potential benefit with important uncertainty

A 2024 meta-analysis suggested improved density in androgenetic alopecia, but studies were highly inconsistent, publication bias was evident and evidence quality was low; its search ended in April 2023. A study average is not your chance of success. Compare PRP with diagnosis-appropriate medication, observation and camouflage. Automatically replacing an established treatment is not justified by a promotional success rate.

Section sources: Meta-analysis · PRP for androgenetic alopecia (2024) · AAD · Male pattern hair loss and treatment options

Set an assessment plan before treatment

Use consistent lighting, parting, scalp areas and wet or dry hair for photographs; camouflage fibres should not confound comparisons. Ask about density measurement, review timing, maintenance and total cost. Disclose medicines, platelet or bleeding disorders and major illnesses. Your sample identity and single-use equipment should be traceable. Do not stop necessary medication yourself to fit a clinic’s routine package.

Section sources: ISHRS · Medical treatments and photobiomodulation evidence · Clinical safety project · Infection prevention during PRP preparation (2025) · Health Canada · Position on PRP and PRF treatments (2019 notice)

Discomfort is not proof of hair growth

Tenderness, pinpoint pain, swelling or bruising may follow injections; greater discomfort does not mean better stimulation. Obtain instructions for washing, exercise and resuming scalp medicines. Persistent itching or scale should not be labelled “follicle activation.” Hair response is assessed over time, rather than from an immediate photograph or one day’s count of hairs in the shower.

Section sources: AAD · Male pattern hair loss and treatment options · AAD · Hair loss signs requiring diagnosis

Separate scalp care from shaft care

When washing is permitted, gentle cleansing and conditioner suited to the hair lengths can reduce mechanical damage; a “growth shampoo” does not replace diagnosis and treatment. Do not put essential oils, scrubs, irritating oils or new serums on open injection sites. If you use minoxidil or another medicine, coordinate its schedule with the clinician and pharmacist; restart timing is not identical for everyone.

Section sources: AAD · Gentle care for fragile and thinning hair · AAD · Hair loss diagnosis and treatment

Symptoms that need prompt attention

Report increasing pain, warmth, spreading redness, drainage or fever promptly; do not conceal a possible infection with serums or home steroid treatment. Painful blisters near an eye, eye pain or visual change need urgent assessment. Call 911 for breathing difficulty, persistent collapse or severe systemic symptoms. Rapid inflammatory hair loss should not wait until a prepaid course is finished.

Section sources: CDC · Surgical site infection symptoms and response · AAD · Hair loss signs requiring diagnosis · Case report · Ocular shingles after scalp PRP (2025; cannot establish frequency)

Frequently asked questions

Related guides to explore

• Low-level light/laser for hair
• Hair transplantation

Sources and context

Canadian sources take priority for regulatory context. FDA or other foreign information does not establish Canadian authorization for a product or use. A source-check date is distinct from publication date or independent clinical approval.

1. Health Canada · Position on PRP and PRF treatments (2019 notice)regulator · 2026-10-17
2. Meta-analysis · PRP for androgenetic alopecia (2024)review · 2026-10-17
3. AAD · Hair loss diagnosis and treatmentsociety · 2026-10-17
4. AAD · Hair loss signs requiring diagnosissociety · 2026-10-17
5. AAD · Causes of hair loss including scarring alopeciasociety · 2026-10-17
6. AAD · Male pattern hair loss and treatment optionssociety · 2026-10-17
7. ISHRS · Medical treatments and photobiomodulation evidencesociety · 2026-10-17
8. Clinical safety project · Infection prevention during PRP preparation (2025)study · 2026-10-17
9. AAD · Gentle care for fragile and thinning hairsociety · 2026-10-17
10. CDC · Surgical site infection symptoms and responsepublic-health · 2026-10-17
11. Case report · Ocular shingles after scalp PRP (2025; cannot establish frequency)case-report · 2026-10-17